Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 21, 2017
Pharmacy Choice - Pharmaceutical News - European Medical Device Firm BrainCool AB Enters US Market with 510(k) Clearance from FDA for IQoolTM System for Temperature Management - September 21, 2017

Pharmacy News Article

 5/17/17 - European Medical Device Firm BrainCool AB Enters US Market with 510(k) Clearance from FDA for IQoolTM System for Temperature Management

LUND, Sweden(BUSINESS WIRE) European medical device firm BrainCool AB has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its first product in the United States, the IQoolTM System, with an indication for use of temperature reduction in adult patients when clinically indicated.

The IQool System is a next-generation precision surface cooling system intended for temperature management with a focus on three independent anatomical zones: head/neck, thigh and torso. The IQool System quickly and effectively cools adult patients when clinically indicated using easy-to-apply non-stick adhesive pads prefilled with BCCOOL (a non-toxic and bacteria-static cooling agent) that are attached to an automated chiller. The IQool engages within seconds, allowing clinicians in a variety of settings to manage patient temperature quickly and effectively.

"Precise and tolerable temperature management can be critical in achieving positive patient outcomes in a large variety of clinical settings. The patented IQool System is designed to work with both sedated and conscious patients, and works with several independent cooling zones of the body to maximize its effectiveness, commented BrainCool CEO Martin Waleij.

Based in Lund, Sweden, Europe, BrainCool AB (publ) (AktieTorget: BRAIN) is a publicly traded medical device company focused on next-generation temperature management systems. The technology platform both cools and warms patients using focused anatomical zones as opposed to whole body applications such as cooling blankets. BrainCool dramatically advances the temperature management standard of care by delivering a physically-targeted, speed-driven temperature management system designed to be easy to use and effective. The company currently markets a number of CE-marked devices in Europe addressing therapeutic hypothermia for cardiac arrest and stroke (BrainCoolTM and RhinoChillTM), with products focused on oncology, traumatic brain injury and pain management currently in development.

This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on May 17, 2017.

BrainCool AB

Martin Waleij, +46733 93 70 76

martin.waleij@braincool.se

or

Lisa Owens, 210-601-6647

LisaMMOwens@gmail.com

Source: BrainCool AB



Copyright Business Wire 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Sep 21: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Last Chance
Sep 22: Influenza 2017-2018: An Update on Prevention and Treatment
Sep 24: Using Effective Communication to Reduce Medication Errors
Sep 25: Management of Major Depressive Disorders
Sep 26: Vitamins, Minerals, and Electrolytes in Older Adults
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415